Presenters
Course Details
Hypertension is one of the most common comorbidities of patients with chronic obstructive pulmonary disease (COPD) and the clinical evidence on the treatment of hypertension in COPD patients is limited. In this webinar held in partnership with the Philippine College of Chest Physicians and the Philippine Academy of Family Physicians, Dr. Ethel Deloso-Añonuevo (Southcity Hospital) discussed the general principles of the management of hypertension in patients with COPD, focusing on the pulmonary effects of antihypertensive medications. Dr. Gilbert Vilela (Philippine Heart Center) then discussed the clinical evidence supporting the use of ARBs in the management of hypertension in COPD patients.
About the speakers
Dr. Ethel Deloso-Añonuevo is the Chief of Clinics and Head of the Pulmonary Unit of the Southcity Hospital and Medical Center. She is also a Consultant of the Section of Pulmonary Medicine of Asian Hospital and Medical Center.
Dr. Gilbert Vilela is the President of the Philippine Heart Association and the Secretary of the Philippine Society of Hypertension. He is also the Deputy Executive Director for Education, Training and Research of the Philippine Heart Center.
Estimated time of Completion: 1 hr. 18 mins. 37 secs.
CPD Points: 1 Point
PRC Program No: PROG-2022-36227
COPD and Hypertension: What’s the connection? Course Outline
Ethel Deloso-Añonuevo, RPh, MD, FPCP, FPCCP – Management of hypertension in COPD patients
- Chronic Obstructive Pulmonary Disease
- Pathobiology of COPD
- Prevalence of Hypertension and COPD in the Philippines
- Mechanism of hypertension in COPD
- CV risk factors in Filipinos with COPD
- Hypertension and COPD Severity
- Hypertension Prevalence/risk by COPD stage
- COPD patients are at increased risk of CVD
- COPD patients are at increased risk of CV death
- Interaction of CVD and COPD
- Treatment of hypertension in COPD
- Diuretics
- If using Diuretics, consider the following
- Calcium Channel Blockers
- Facts about Calcium Channel Blockers in COPD
- Beta-blockers
- Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison
- Metoprolol for the Prevention of Acute Exacerbations of COPD
- COPD, Heart failure and Beta blockers
- Other agents
- ACEI/ARBs
- Summary
Gilbert C. Vilela, MD, FPCP, FPCC – Why ARBs in the treatment of Hypertension in COPD patients?
- Individualized Care
- Risk Factor Counting
- Symptom Associated with 50% increase in the risk for coronary deaths
- Appropriate Risk Factor Management
- Progress in the mechanism and targeting drug therapy for COPD
- ARBs and COPD: Mechanisms
- Inflammatory mediators stimulated by angiotensin II
- Action of RAAS blockade in COPD
- Effects of ARBs in airway and cardiac remodeling
- ARB outcome studies in patients with COPD
- ARBs and COD progression: MESA Lung study
- ARBs and risk of pneumonia in COPD
- ARBs and COPD patients
- ARBs and COPD mortality
- Can we consider COPD patients as “high-risk patients”?
- The leading causes of mortality in those with obstructive airways disease are cardiovascular in nature
- ISH 2020: Ideal characteristics of drug treatment
- Pharmacological Profile of Telmisartan
- Comparative Pharmacokinetic Profile
- ONTARGET
- Telmisartan is As Effective As Ramipril in preventing individual CV Events at Increased CV Risk
- Telmisartan is As Effective As Ramipril in Preventing CV Events at Increased CV Risk
- If COPD increases CVD risk, is Telmisartan compelling enough for risk reduction among COPD patients with hypertension
- Summary
PC-PH-103169 / September 2023